Enrique Grande Pulido-rekin lankidetzan egindako argitalpenak (5)

2021

  1. Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

    Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312

2020

  1. The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)

    Oncologist, Vol. 25, Núm. 9, pp. 745-e1265

2019

  1. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)

    British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544

2017

  1. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)

    European Journal of Endocrinology, Vol. 177, Núm. 4, pp. 309-317

  2. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: A Spanish multicenter experience

    Future Oncology, Vol. 13, Núm. 7, pp. 615-624